This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Related links
PowerPoint slides
Rights and permissions
About this article
Cite this article
Harrison, R. Phase II and phase III failures: 2013–2015. Nat Rev Drug Discov 15, 817–818 (2016). https://doi.org/10.1038/nrd.2016.184
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2016.184
This article is cited by
-
From understanding diseases to drug design: can artificial intelligence bridge the gap?
Artificial Intelligence Review (2024)
-
The Role of Genetics in Advancing Cardiometabolic Drug Development
Current Atherosclerosis Reports (2024)
-
In-silico target prediction by ensemble chemogenomic model based on multi-scale information of chemical structures and protein sequences
Journal of Cheminformatics (2023)
-
Mendelian randomization studies of depression: evidence, opportunities, and challenges
Annals of General Psychiatry (2023)
-
Modeling drug-induced liver injury and screening for anti-hepatofibrotic compounds using human PSC-derived organoids
Cell Regeneration (2023)